Supplementary Table 4. Comparison of baseline characteristics between matched cohorts: TACE vs. non-sorafenib

Characteristic	Treatment		P-value
	TACE (n=39)	Non-sorafenib (n=39)	
Age (years)	57.0±10.2	56.7±11.4	0.925
Male	33 (84.6)	35 (89.7)	0.735
Etiology			1.000
Viral	31 (79.5)	30 (76.9)	
NBNC	8 (20.5)	9 (23.1)	
ECOG performance status			1.000
0	34 (87.2)	34 (87.2)	
≥1	5 (12.8)	5 (12.8)	
ALBI grade			1.000
1	26 (66.7)	27 (69.2)	
≥2	13 (33.3)	12 (30.8)	
Size (cm)			1.000
<5	6 (15.4)	5 (12.8)	
≥5	33 (84.6)	34 (87.2)	
Number			1.000
<3	13 (33.3)	14 (35.9)	
≥3	26 (66.7)	25 (64.1)	
Log (AFP)	5.8±3.7	6.2±3.7	0.705
Log (PIVKA-II)	7.9±2.7	7.6±2.9	0.610
PV invasion			0.201
None	18 (46.2)	17 (43.6)	
Segmental/lobar	16 (41.0)	11 (28.2)	
Main/contralateral	5 (12.8)	11 (28.2)	
Extrahepatic metastasis type			0.389
Nodal metastasis	16 (41.0)	19 (48.7)	
Distant metastasis	16 (41.0)	17 (43.6)	
Nodal plus distant metastasis	7 (17.9)	3 (7.7)	

Values are presented as mean±standard deviation or number (%).

TACE, transarterial chemoembolization; NBNC, non-B and non-C; ECOG, Eastern Cooperative Oncology Group; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II; PV, portal vein.